Bruker Balance Sheet Health

Financial Health criteria checks 4/6

Bruker has a total shareholder equity of $1.4B and total debt of $1.2B, which brings its debt-to-equity ratio to 87.3%. Its total assets and total liabilities are $4.2B and $2.8B respectively. Bruker's EBIT is $484.1M making its interest coverage ratio 54.4. It has cash and short-term investments of $500.3M.

Key information

87.3%

Debt to equity ratio

US$1.23b

Debt

Interest coverage ratio54.4x
CashUS$500.30m
EquityUS$1.41b
Total liabilitiesUS$2.84b
Total assetsUS$4.25b

Recent financial health updates

Recent updates

Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)

Jan 22
Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)

There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price

Jan 08
There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price

Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?

Dec 26
Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?

Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?

Nov 06
Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?

Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Oct 23
Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors

Sep 25
Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors

Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?

Aug 09
Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?

Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?

Jul 27
Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?

Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet

Jul 11
Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet

If EPS Growth Is Important To You, Bruker (NASDAQ:BRKR) Presents An Opportunity

Jun 26
If EPS Growth Is Important To You, Bruker (NASDAQ:BRKR) Presents An Opportunity

Is It Time To Consider Buying Bruker Corporation (NASDAQ:BRKR)?

Apr 25
Is It Time To Consider Buying Bruker Corporation (NASDAQ:BRKR)?

These 4 Measures Indicate That Bruker (NASDAQ:BRKR) Is Using Debt Reasonably Well

Apr 07
These 4 Measures Indicate That Bruker (NASDAQ:BRKR) Is Using Debt Reasonably Well

Bruker (NASDAQ:BRKR) Ticks All The Boxes When It Comes To Earnings Growth

Feb 20
Bruker (NASDAQ:BRKR) Ticks All The Boxes When It Comes To Earnings Growth

Why Bruker Corporation (NASDAQ:BRKR) Could Be Worth Watching

Jan 17
Why Bruker Corporation (NASDAQ:BRKR) Could Be Worth Watching

Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Dec 30
Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Should You Think About Buying Bruker Corporation (NASDAQ:BRKR) Now?

Oct 16
Should You Think About Buying Bruker Corporation (NASDAQ:BRKR) Now?

Here's Why We Think Bruker (NASDAQ:BRKR) Is Well Worth Watching

Oct 03
Here's Why We Think Bruker (NASDAQ:BRKR) Is Well Worth Watching

Estimating The Intrinsic Value Of Bruker Corporation (NASDAQ:BRKR)

Sep 19
Estimating The Intrinsic Value Of Bruker Corporation (NASDAQ:BRKR)

Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Sep 05
Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Bruker Corporation: Upside Is Limited From Here

Aug 24

Bruker declares $0.05 dividend

Aug 12

Financial Position Analysis

Short Term Liabilities: BRKR's short term assets ($2.2B) exceed its short term liabilities ($1.2B).

Long Term Liabilities: BRKR's short term assets ($2.2B) exceed its long term liabilities ($1.6B).


Debt to Equity History and Analysis

Debt Level: BRKR's net debt to equity ratio (51.9%) is considered high.

Reducing Debt: BRKR's debt to equity ratio has increased from 36% to 87.3% over the past 5 years.

Debt Coverage: BRKR's debt is well covered by operating cash flow (28.4%).

Interest Coverage: BRKR's interest payments on its debt are well covered by EBIT (54.4x coverage).


Balance Sheet


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.